Skip to main content

Table 4 Association between genetic variants and erythropoiesis stimulating agents (ESA) or colony stimulating factor (CSF) use

From: Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

4A: Significant correlations with ESA use
  All patients Patients with ESA use Patients without ESA use Unadjusted OR (95%CI) *p-value Adjusted OR (95% CI) **Corrected p value
N = 290 (%) N = 70 (24.2%) N = 219 (75.8%)
ABCC1 rs2074087 GG 215 (74.4) 46 (65.7) 169 (77.2) 1.78 (1.03- 3.08) 0.054 2.09 (1.18 - 3.68) 0.011
GC 69 (23.9) 22 (31.4) 47 (21.5)  
CC 5 (1.7) 2 (2.8) 3 (1.4)  
4B: Significant correlations with CSF use
  All patients Patients with CSF use Patients without CSF use Unadjusted OR *p-value Adjusted OR **Corrected p value
N = 290 (%) N = 62 (21.4%) N = 228 (78.6%) (95%CI) (95% CI)
ABCC2 rs2073337 AA 101 (34.8) 27 (43.5) 74 (32.5) 0.61 (0.39- 0.96) 0.031 0.60 (0.37-0.99) 0.039
AG 148 (51.0) 31 (50.0) 117 (51.3)
GG 41 (14.1) 4 (6.5) 37 (16.2)
GSTP1 rs1695 AA 121 (41.7) 33 (53.2) 88 (38.6) 0.54 (0.34; 0.86) 0.010 0.55 (0.33-0.90) 0.017
AG 137 (47.2) 27 (43.5) 110 (48.2)
GG 32 (11.0) 2 (3.2) 30 (13.2)
ERCC2 Rs1799793 GG 136 (48.2) 21 (33.9) 115 (50.4) 0.67 (0.45- 1.00) 0.048 0.63 (0.41-0.98) 0.042
GA 111 (39.4) 30 (48.4) 81 (35.5)
AA 35 (12.4) 9 (14.5) 26 (11.4)
  1. OR: Odds Ratio using wild type as reference category. *Uncorrected p values were calculated using binary logistic regression for the need for ESA/CSF use without correction for covariates. Per-allele ORs and 95% CIs are shown. There were missing genotypes for rs2074087 (n = 1), rs1799793 (n = 8). **Corrected p values were obtained using a logistic regression for the need for ESA/CSF use while including the following covariates: genetic variants, age, BMI, dosage of carboplatin (AUC) and number of administered cycles.